Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.

Santiago Ponce-Aix,Gregory M. Cote,Alejandro Gonzalez,Juan Manuel Sepúlveda,Elizabeth Jimenez Aguilar,Inmaculada Sanchez-Simon,María José Flor,Rafael Núñez,Eva María González,Monica Insa,Mariano Siguero,M. Cullell-Young,Carmen Kahatt,Ali Zeaiter,Luis Paz-Ares

Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.

2020

Santiago Ponce-Aix
Gregory M. Cote
Alejandro Gonzalez
Juan Manuel Sepúlveda
Elizabeth Jimenez Aguilar
Inmaculada Sanchez-Simon
María José Flor
Rafael Núñez
Eva María González
Monica Insa
Mariano Siguero
M. Cullell-Young
Carmen Kahatt
Ali Zeaiter
Luis Paz-Ares

3514Background: LUR is a novel agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in...

Keywords:

Lurbinectedin
Irinotecan
Internal medicine
Oncology
Medicine
in patient
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations